Amgen spotlights preclinical ‘multi-specifics’ as analyst predicts late-stage M&A

If David Reese gets his way, Lumakras will be the first of many Amgen drugs that shatter the fences currently cordoning off vast swaths of protein targets as “undruggable.” Lumakras, the groundbreaking KRAS G12C inhibitor 40 years in the making, did not disappoint during its first months as a commercial…

...

Click to view original post